Advances in the biology of astrocytomas
Abhijit Guha1, Joydeep Mukherjee
1Western Hospital, University of Toronto, Toronto, Ontario M5T 2S8, Canada. abhijit@uhn.on.ca
Purpose Of Review:
Conventional surgery, radio- and chemotherapy have failed to significantly improve the prognosis of patients with malignant astrocytomas--hence the need for understanding their molecular biology. Harvesting this understanding to yield novel biological targeted therapies has approached the clinical doorstep. Therapeutic efficacy will likely require combinatorial therapy involving biologicals and conventional therapies, with small incremental efficacy in selected sub-groups. This review highlights some of the findings over the past year (June 2003-2004) that have contributed to this slow but essential journey towards our understanding of the biology of astrocytomas.
Recent Findings:
The accumulation of loss and/or gain of function molecular alterations underlying astrocytoma formation, progression and key growth parameters including proliferation, angiogenesis, apoptosis, invasion and resistance are emerging. These alterations involve those regulating the growth factor/receptor and downstream signaling networks, cell cycle, immune modulators and other key biological processes. The advances are facilitated by interactions amongst clinician and basic scientists, in both academia and industry. They have incorporated high-throughput bioinformatics analysis of genomic and expression array data, the emerging field of proteomics and development of various genetically engineered models of astrocytomas.
Summary:
Astrocytomas, like other cancers, are a result of several molecular alterations, some of which strongly correlate to their pathological grade. However, molecular heterogeneity exists between astrocytomas of similar grades and likely between varying micro-environmental regions of a single tumor. Characterization of the molecular signature of an astrocytoma and linking with the appropriate 'tailored' therapie(s) is the hope of the future.
Insights
Understanding astrocytoma molecular biology is crucial for developing targeted therapies. Recent findings reveal key molecular alterations driving astrocytoma growth, paving the way for personalized treatments.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genomics and Proteomics
Background:
- Conventional treatments for malignant astrocytomas offer limited patient prognosis improvement.
- Understanding astrocytoma molecular biology is essential for developing novel targeted therapies.
Purpose of the Study:
- To review recent findings (June 2003-2004) advancing the understanding of astrocytoma molecular biology.
- To highlight progress towards novel biological targeted therapies for astrocytomas.
Main Methods:
- Analysis of molecular alterations in astrocytoma formation and progression.
- Integration of high-throughput bioinformatics, proteomics, and genetically engineered models.
- Collaboration between academic and industrial researchers.
Main Results:
- Identification of molecular alterations affecting proliferation, angiogenesis, apoptosis, invasion, and resistance.
- Insights into dysregulated growth factor/receptor signaling, cell cycle, and immune modulation.
- Recognition of molecular heterogeneity within astrocytomas.
Conclusions:
- Astrocytomas arise from multiple molecular alterations correlated with pathological grade.
- Significant molecular heterogeneity exists between tumors and within individual tumors.
- Future therapeutic strategies will likely involve tailored treatments based on individual astrocytoma molecular signatures.
